GramEye Secures ¥570M Series B Funding Led by Beyond Next Ventures

Why It Matters

The capital infusion positions GramEye to scale its diagnostic platform, potentially reshaping clinical workflows and capturing market share in a rapidly digitizing healthcare sector.

Deal Summary

Osaka‑based GramEye announced a Series B round of ¥570 million, led by Beyond Next Ventures with participation from existing backers Samurai Incubate and NES Inc. The AI‑driven diagnostic device maker will use the capital to accelerate product development and market expansion.